Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025

Reuters10-14

Spero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025

Spero Therapeutics Inc., a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections (cUTI), including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544842-en) on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575972682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575972682","market":"nz","top_or_hot":-1,"title":"Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRO\">Spero Therapeutics Inc.</a>, a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections (cUTI), including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544842-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRO\">Spero Therapeutics Inc.</a>, a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections (cUTI), including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544842-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLbfDNkx:1","article_id":"2575972682","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575972682","pubTimestamp":1760443260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025. Spero Therapeutics Inc., a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections , including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.Disclaimer: This news brief was created ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SPRO":"Spero Therapeutics Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Spero Therapeutics在IDWeek 2025上宣布口服替比培南治疗复杂尿路感染的3期PIVOT-PO试验结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRO":0.9,"NDAQ":0.9},"content_text":"Spero Therapeutics Announces Positive Phase 3 PIVOT-PO Trial Results for Oral Tebipenem in Complicated Urinary Tract Infections at IDWeek 2025\n    \n\nSpero Therapeutics Inc., a clinical-stage biopharmaceutical company, announced upcoming presentations on its investigational oral carbapenem, tebipenem Hbr, at the IDWeek annual meeting taking place October 19-22, 2025, in Atlanta, GA. The presentations will include efficacy and safety results from the Phase 3 PIVOT-PO trial evaluating tebipenem Hbr in patients with complicated urinary tract infections (cUTI), including pyelonephritis. The oral presentation is scheduled for October 20, 2025. Additionally, poster presentations will cover the antibacterial spectrum and activity of tebipenem against Enterobacterales clinical isolates from the United States and United Kingdom, with results to be presented on October 21, 2025. These presentations are being made in collaboration with Spero's development partner, GSK.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544842-en) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575972682","isCrawlerRequest":true}